Modis Therapeutics
Acquired by Zogenix
Develops targeted therapies for rare genetic diseases and mitochondrial disorders.
Develops targeted therapies for rare genetic diseases and mitochondrial disorders.
F-Prime Team
Sector
Life SciencesCategory
TherapeuticsLocation
Oakland, CAInitial Investment
2018Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.